H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
AmJCaseRep

Annals
ISI-Home

Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

Ruixue Tang, Lu Liang, Dianzhong Luo, Zhenbo Feng, Qiuxia Huang, Rongquan He, Tingqing Gan, Lihua Yang, Gang Chen

Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland)

Med Sci Monit 2015; 21:2514-2520

DOI: 10.12659/MSM.894372

Available online:

Published: 2015-08-25


BACKGROUND: Recent reports have suggested that miR-30a plays a tumor-suppressive role in various cancers. However, miR-30a has not been completely studied in non-small lung cancer (NSCLC). Thus, the aim of the present study was to clarify the association between the expression of miR-30a and the clinicopathological features in NSCLC patients.
MATERIAL AND METHODS: Total RNA of miR-30a was extracted from 125 pairs of NSCLC patients (male 75, female 50) and their matching normal tissues. The miR-30a level was detected by using quantitative real-time polymerase chain reaction (qRT-PCR). Simultaneously, the 2–ΔCq method was used to calculate the correlation between miR-30a expression and the clinicopathological parameters and prognosis of NSCLC patients.
RESULTS: MiR-30a expression was significantly down-regulated in NSCLC tissues (4.0696±2.4178) compared to their non-tumor lung tissues (7.4530±3.0561, P<0.001). Level of miR-30a was negatively correlated to tumor size (r=–0.197, P=0.028), lymphatic metastasis (r=–0.312, P<0.001), clinical TNM stage (r=–0.299, P=0.001), pathological grading (I/II vs. III, r=–0.224, P=0.001), and histological classification (r=–0.299, P=0.001). Survival time was 3.23±2.18 months in the low miR-30a expression group, remarkably shorter than that of the high expression group (20.72±11.63 months, P<0.001).
CONCLUSIONS: MiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.

Keywords: Aged, 80 and over, Adult, Biomarkers, Tumor - genetics, Carcinoma, Non-Small-Cell Lung - secondary, Down-Regulation, Kaplan-Meier Estimate, Lung Neoplasms - pathology, Lymphatic Metastasis - pathology, MicroRNAs - metabolism, Prognosis, RNA, Neoplasm - metabolism, Real-Time Polymerase Chain Reaction, young adult



Back